AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10715760 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stroke group
Number of subjects: 80
Study 10715760 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 10715760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 8538891 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal medication counseling from a pharmacist
Number of subjects: 70
Study 8538891 — intervention group
Group type: COMPARATOR
Intervention: No verbal medication counseling (uncounseled)
Number of subjects: 70
Study 1837743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg IV before cisplatin, then 1 mg/h for 24 hours; oral 8 mg three times daily on days 2-6) plus Dexamethasone (20 mg IV)
Number of subjects: 100
Study 1837743 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg IV before cisplatin, then 1 mg/h for 24 hours; oral 8 mg three times daily on days 2-6)
Number of subjects: 100
Study 1837743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Ondansetron + Dexamethasone)
Number of subjects: 100
Study 7150458 — intervention group
Group type: EXPERIMENTAL
Intervention: C 49802 B‐Ba
Number of subjects: 8
Study 7150458 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 12103/A
Number of subjects: 8
Study 7150458 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 8
Study 7150458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31990967 — intervention group
Group type: EXPERIMENTAL
Intervention: HERO Wellness Scale
Number of subjects: 84
Study 31990967 — intervention group
Group type: COMPARATOR
Intervention: WHO‐5 Well‐Being Index
Number of subjects: 84
Study 31311668 — intervention group
Group type: EXPERIMENTAL
Intervention: Temelimab at doses of 36, 60, 85, and 110 mg/kg
Number of subjects: 24
Study 31311668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28937446 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopy
Number of subjects: 101
Study 28937446 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopy
Number of subjects: 101
Study 24449558 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisible social support
Number of subjects: 73
Study 24449558 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-confounded visible social support
Number of subjects: 73
Study 24449558 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible social support (as delivered in a 2007 study by Bolger and Amarel)
Number of subjects: 73
Study 24449558 — intervention group
Group type: COMPARATOR
Intervention: No social support
Number of subjects: 73
Study 24449558 — intervention group
Group type: COMPARATOR
Intervention: Control and replication conditions
Number of subjects: 73
Study 24171301 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ivermectin (1% applied at 400 microg/kg, repeated once the following week)
Number of subjects: 380
Study 24171301 — intervention group
Group type: COMPARATOR
Intervention: Permethrin 2.5% cream (applied twice at one week intervals)
Number of subjects: 380
Study 21733058 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg (Alo25) added to Metformin and Pioglitazone
Number of subjects: 803
Study 21733058 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 15 mg (Met+Pio45)
Number of subjects: 803
Study 19318791 — intervention group
Group type: EXPERIMENTAL
Intervention: Online course of instruction
Number of subjects: 16
Study 19318791 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face course of instruction
Number of subjects: 16
Study 16400465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg loading dose before incision, followed by 1 mg/kg/h for 5 hours)
Number of subjects: 65
Study 16400465 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline bolus and continuous infusion for 5 hours)
Number of subjects: 65
Study 15262026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with midazolam elixir
Number of subjects: 18
Study 15262026 — intervention group
Group type: COMPARATOR
Intervention: Analgesia with morphine sulphate
Number of subjects: 18
Study 15262026 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with dextromoramide and lorazepam
Number of subjects: 18
Study 11706519 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for bloodstream infections
Number of subjects: 0
Study 11706519 — intervention group
Group type: COMPARATOR
Intervention: Intravascular catheters
Number of subjects: 0
Study 9250038 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine nursing care combined with eggcrate foam (n=20)
Number of subjects: 50
Study 9250038 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine nursing care combined with hydrocolloid dressing (n=15)
Number of subjects: 50
Study 9250038 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care alone (n=15)
Number of subjects: 50
Study 8103382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 20
Study 8103382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2935644 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg diethylstilbestrol orally 3 times daily
Number of subjects: 465
Study 2935644 — intervention group
Group type: COMPARATOR
Intervention: 250 mg oral cyproterone acetate daily
Number of subjects: 465
Study 2935644 — intervention group
Group type: COMPARATOR
Intervention: 500 mg medroxyprogesterone acetate intramuscularly 3 times weekly for 8 weeks, then 200 mg orally daily
Number of subjects: 465
Study 2935644 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg diethylstilbestrol
Number of subjects: 465
Study 2935644 — intervention group
Group type: COMPARATOR
Intervention: 560 mg estramustine phosphate orally for 8 weeks, then 280 mg daily
Number of subjects: 465
Study 30041701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (POM) supplementation, 50 ml daily for two months
Number of subjects: 19
Study 30041701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (POM) supplementation
Number of subjects: 19
Study 30041701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30041701 — intervention group
Group type: COMPARATOR
Intervention: Both groups (POM and placebo)
Number of subjects: 19
Study 27029363 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposed group (average concentration of cadmium >0.40 mg/kg in rice and >1.0 mg/kg in soil)
Number of subjects: 414
Study 27029363 — intervention group
Group type: COMPARATOR
Intervention: Low exposed group (average concentration of cadmium 0.15-0.40 mg/kg in rice and 0.5-1.0 mg/kg in soil)
Number of subjects: 414
Study 27029363 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 414
Study 27029363 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable samples
Number of subjects: 414
Study 25398670 — intervention group
Group type: EXPERIMENTAL
Intervention: CC genotype of rs324148
Number of subjects: 100
Study 25398670 — intervention group
Group type: EXPERIMENTAL
Intervention: CC genotype of rs9394992
Number of subjects: 100
Study 25398670 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse karyotypes
Number of subjects: 100
Study 23387950 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based peer intervention
Number of subjects: 200
Study 23387950 — intervention group
Group type: COMPARATOR
Intervention: Control city (no intervention)
Number of subjects: 200
Study 20492853 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose paliperidone ER (12 mg/d)
Number of subjects: 316
Study 20492853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose paliperidone ER (6 mg/d)
Number of subjects: 316
Study 20492853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 20492853 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (both doses)
Number of subjects: 316
Study 18954708 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifications as surrogates for prostate position during CBCT image-guided radiotherapy
Number of subjects: 131
Study 18954708 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CBCT imaging
Number of subjects: 131
Study 18954708 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CBCT imaging
Number of subjects: 131
Study 15992986 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectilinear biphasic (RLB) waveform (120, 150, 200J)
Number of subjects: 169
Study 15992986 — intervention group
Group type: COMPARATOR
Intervention: Monophasic damped sine (MDS) waveform (200, 300, 360J)
Number of subjects: 169
Study 15992986 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectilinear biphasic (RLB) waveform
Number of subjects: 169
Study 15992986 — intervention group
Group type: COMPARATOR
Intervention: Monophasic damped sine (MDS) waveform
Number of subjects: 169
Study 15992986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander witnessed events (RLB)
Number of subjects: 169
Study 15992986 — intervention group
Group type: COMPARATOR
Intervention: Bystander witnessed events (MDS)
Number of subjects: 169
Study 12953145 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training (S)
Number of subjects: 39
Study 12953145 — intervention group
Group type: COMPARATOR
Intervention: Self-monitored training (SM)
Number of subjects: 39
Study 12953145 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance program (MP)
Number of subjects: 39
Study 11060418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (low molecular weight heparin)
Number of subjects: 24497
Study 11060418 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 24497
Study 11060418 — intervention group
Group type: COMPARATOR
Intervention: Low risk (no prevention)
Number of subjects: 24497
Study 8800307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadexomer iodine ointment (Iodosorb)
Number of subjects: 25
Study 8800307 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (gentamicin solution, streptodornase/streptokinase, or dry saline gauze)
Number of subjects: 25
Study 8800307 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 25
Study 1320306 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (720 EIU, 3 doses, 0, 1 month schedule, booster at month 6)
Number of subjects: 204
Study 1320306 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (3 consecutive lots)
Number of subjects: 204
Study 6480953 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (10 mg three times daily)
Number of subjects: 9
Study 6480953 — intervention group
Group type: COMPARATOR
Intervention: Cyproheptadine (4 mg three times daily)
Number of subjects: 9
Study 6480953 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine (10 mg three times daily)
Number of subjects: 9
Study 6480953 — intervention group
Group type: COMPARATOR
Intervention: Cinnarizine (10 mg three times daily)
Number of subjects: 9
Study 31226579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) technology for momentary assessments of persecutory ideation (PI)
Number of subjects: 62
Study 31226579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) technology for momentary assessments of PI
Number of subjects: 62
Study 29769060 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable inflatable balloon
Number of subjects: 0
Study 29769060 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 26973262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 8 weeks in addition to routine postoperative treatment
Number of subjects: 75
Study 26973262 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative treatment only (Control)
Number of subjects: 75
Study 25325925 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemfola pen (BP)
Number of subjects: 0
Study 25325925 — intervention group
Group type: EXPERIMENTAL
Intervention: Puregon pen (PP)
Number of subjects: 0
Study 25325925 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonal-f pen (GP)
Number of subjects: 0
Study 22773286 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal treatment of maternal periodontitis
Number of subjects: 331
Study 22773286 — intervention group
Group type: COMPARATOR
Intervention: Postpartum treatment of maternal periodontitis
Number of subjects: 331
Study 19852869 — intervention group
Group type: COMPARATOR
Intervention: Distortion product otoacoustic emissions
Number of subjects: 26
Study 19852869 — intervention group
Group type: COMPARATOR
Intervention: Transient evoked otoacoustic emissions
Number of subjects: 26
Study 19852869 — intervention group
Group type: COMPARATOR
Intervention: Pure tone audiometry
Number of subjects: 26
Study 17978257 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery program
Number of subjects: 210
Study 17978257 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 210
Study 17176801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cytology using the Rhinoprobe method
Number of subjects: 90
Study 17176801 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonatopic children)
Number of subjects: 90
Study 11894031 — intervention group
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate (OCA)
Number of subjects: 814
Study 11894031 — intervention group
Group type: COMPARATOR
Intervention: Standard wound closure methods (SWC)
Number of subjects: 814
Study 9867068 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (PE)
Number of subjects: 45
Study 9867068 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 45
Study 8595687 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of the laryngeal mask airway by anaesthetist in deeply anaesthetised patients
Number of subjects: 100
Study 8595687 — intervention group
Group type: COMPARATOR
Intervention: Removal of the laryngeal mask airway by nurse in awake patients
Number of subjects: 100
Study 8595687 — intervention group
Group type: COMPARATOR
Intervention: Control group (anaesthetised patients)
Number of subjects: 100
Study 2774262 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose solution
Number of subjects: 20
Study 2774262 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 20
Study 31538810 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C for 24 h
Number of subjects: 240
Study 31538810 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C for 48 h
Number of subjects: 240
Study 31538810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MAp19 levels at admission
Number of subjects: 240
Study 31538810 — intervention group
Group type: EXPERIMENTAL
Intervention: MAp19 levels at 24-72 h
Number of subjects: 240
Study 31538810 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 240
Study 31495577 — intervention group
Group type: EXPERIMENTAL
Intervention: ROP position + pacifier (experimental group, n=35)
Number of subjects: 70
Study 31495577 — intervention group
Group type: COMPARATOR
Intervention: Pacifier only (control group, n=35)
Number of subjects: 70
Study 29019927 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet adherence (high MDS)
Number of subjects: 0
Study 29019927 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet adherence (high MDS) among subjects with high Genetic Risk Score (GRS)
Number of subjects: 0
Study 29019927 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet adherence (low GRS)
Number of subjects: 0
Study 25927870 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus additional Saturday rehabilitation
Number of subjects: 996
Study 25927870 — intervention group
Group type: COMPARATOR
Intervention: Usual care rehabilitation services from Monday to Friday
Number of subjects: 996
Study 23020608 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 217
Study 23020608 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 217
Study 21733413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program from a clinical pharmacist
Number of subjects: 200
Study 21733413 — intervention group
Group type: COMPARATOR
Intervention: Usual care from medical and nursing staff
Number of subjects: 200
Study 19663109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional photothermolysis (AFP)
Number of subjects: 10
Study 16675610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mug once daily for 7-10 days
Number of subjects: 18
Study 16675610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15798822 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond SOLO
Number of subjects: 60
Study 15798822 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgambond Plus
Number of subjects: 60
Study 15798822 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0
Number of subjects: 60
Study 12001701 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoablative therapy including high dose cytotoxic agents and hematopoietic autologous stem‐cell rescue
Number of subjects: 0
Study 12001701 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐myeloablative allogeneic transplantation and sub‐myeloblative high dose cyclophosphamide without stem cell support
Number of subjects: 0
Study 12001701 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 9572809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose solution (0.75 g/kg body wt)
Number of subjects: 8
Study 9572809 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 8
Study 8586807 — intervention group
Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (250 mg by intravenous infusion for 5 min)
Number of subjects: 7
Study 8586807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2768617 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped coping model and film distraction technique
Number of subjects: 11
Study 2768617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 11
Study 779796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (average dose: 1.8 mg/kg/day)
Number of subjects: 24
Study 779796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide after crossover
Number of subjects: 24
Study 779796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 779796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 24
Study 31860942 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure of amputation stump
Number of subjects: 56
Study 31860942 — intervention group
Group type: COMPARATOR
Intervention: Delayed primary closure of amputation stump
Number of subjects: 56
Study 27842926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation via feeding jejunostomy (600 kcal/day)
Number of subjects: 44
Study 27842926 — intervention group
Group type: COMPARATOR
Intervention: No jejunal supplement (Control)
Number of subjects: 44
Study 26329976 — intervention group
Group type: COMPARATOR
Intervention: Normal liver (F0)
Number of subjects: 215
Study 26329976 — intervention group
Group type: COMPARATOR
Intervention: Fibrosis without cirrhosis (F1–3)
Number of subjects: 215
Study 26329976 — intervention group
Group type: COMPARATOR
Intervention: Cirrhosis (F4)
Number of subjects: 215
Study 26329976 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (normal, fibrotic, cirrhotic)
Number of subjects: 215
Study 23329881 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy+rh‐endostatin
Number of subjects: 70
Study 21628084 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection
Number of subjects: 38
Study 21628084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 19467028 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper oxide containing pillowcases (0.4% weight/weight)
Number of subjects: 57
Study 17277036 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg vildagliptin daily
Number of subjects: 544
Study 17277036 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg vildagliptin daily
Number of subjects: 544
Study 17277036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 15489367 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluoride mouthrinse/toothpaste treatment regime
Number of subjects: 26
Study 15489367 — intervention group
Group type: COMPARATOR
Intervention: Non-active control combination
Number of subjects: 26
Study 11574431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (multiple daily injections or continuous subcutaneous infusion with frequent blood-glucose testing)
Number of subjects: 1246
Study 11574431 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (1-2 injections of insulin per day)
Number of subjects: 1246
Study 11574431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1246
Study 11574431 — intervention group
Group type: COMPARATOR
Intervention: Intensive therapy and Conventional therapy
Number of subjects: 1246
Study 9213289 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 9213289 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic medications
Number of subjects: 0
Study 9316669 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5-2.5 mg/day)
Number of subjects: 12
Study 9316669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30997730 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyphenol extra virgin olive oil (EVOO)
Number of subjects: 50
Study 30997730 — intervention group
Group type: COMPARATOR
Intervention: Low polyphenol olive oil
Number of subjects: 50
Study 29190252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular distilled water application using vitrectomy approach
Number of subjects: 0
Study 29190252 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0